Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. by Bykerk, Vivian P et al.
BRIEF REPORT
Comparison of tocilizumab as monotherapy or with add-on
disease-modifying antirheumatic drugs in patients
with rheumatoid arthritis and inadequate responses to previous
treatments: an open-label study close to clinical practice
Vivian P. Bykerk & Andrew J. K. Östör & José Alvaro-Gracia & Karel Pavelka &
José Andrés Román Ivorra & Winfried Graninger & William Bensen &
Michael T. Nurmohamed & Andreas Krause & Corrado Bernasconi & Maher Aassi &
Jean Sibilia
Received: 13 February 2014 /Revised: 18 December 2014 /Accepted: 22 December 2014 /Published online: 22 January 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract This was an exploratory analysis comparing the
safety and efficacy of tocilizumab monotherapy with those
of tocilizumab in combination with disease-modifying anti-
rheumatic drugs (DMARDs). Data were from a single-arm,
nonrandomized, open-label, 24-week study in patients with
rheumatoid arthritis in which patients with inadequate re-
sponses to DMARDs or tumor necrosis factor-α inhibitors
received tocilizumab 8 mg/kg intravenously every 4 weeks
plus methotrexate/other DMARD(s) combination therapy. If
they were intolerant of methotrexate/other DMARD, patients
received tocilizumab monotherapy. Effectiveness endpoints
included American College of Rheumatology (ACR) re-
sponses (ACR20/50/70/90) and disease activity score using
28 joints (DAS28). Of 1,681 patients, 239 received toci-
lizumab monotherapy, and 1,442 received combination thera-
py. Methotrexate was the most common DMARD (79 %)
used in combination therapy. The frequency of adverse events
(AEs), serious AEs, and AEs leading to withdrawal were
similar between tocilizumab monotherapy (82.4, 7.9, and
5.4 %, respectively) and combination therapy (76.6, 7.8, and
5.1 %, respectively). No differences in ACR20/50/70/90 re-
sponses were observed between treatment groups (66.9 %/
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43.5 %/23.8 %/10.0 % vs 66.9 %/47.2 %/26.8 %/8.5 %,
respectively; p>0.12 for all individual comparisons, including
ACR50 propensity score analyses). The decrease in DAS28
was also similar between treatment groups (mean±standard
deviation: −3.41±1.49 for tocilizumab monotherapy vs −3.43
±1.43 for combination therapy; p>0.33 all analyses, including
propensity score analyses). Tocilizumab had a comparable
safety profile, and was similarly effective, when used as
monotherapy or in combination with DMARDs in a broad
population of patients with rheumatoid arthritis.
Keywords Disease activity . DMARDs (biologic) .
DMARDs (synthetic) .Monotherapy . Open-label .
Rheumatoid arthritis . Tocilizumab . Tumor necrosis factor-α
inhibitor
Introduction
The current recommendation for patients with rheumatoid
arthritis (RA) not responding adequately to methotrexate
(MTX) or other disease-modifying antirheumatic drugs
(DMARDs) is to coadminister a biologic [1]. However, ap-
proximately one-third of RA patients treated with biologics
receive them as monotherapy (without DMARDs) [2]. Pa-
tients may discontinue DMARDs because of toxicity [3],
contraindications, or personal choice [4].
The safety and efficacy of tocilizumab have been demon-
strated in RA patients who have inadequate responses toMTX/
DMARDs (MTX/DMARD-IR) or tumor necrosis factor-α
inhibitor (TNFi) agents (TNFi-IR) [5]. Tocilizumab monother-
apy has been demonstrated to be more effective than MTX [6,
7] or DMARD [8] monotherapy. Further, tocilizumab com-
bined with MTX has not been shown to be superior to toci-
lizumab monotherapy in MTX-IR patients [9]. In ACT-SURE,
a previously reported nonrandomized, open-label study, toci-
lizumab was administered under conditions more typical of
clinical practice [10]; investigators could administer toci-
lizumab as monotherapy or combined with DMARDs at their
discretion if the patient was able to tolerate DMARDs. Here we
describe and compare these two treatment approaches.
Methods
Study design
In this 24-week, phase 3b, single-arm, nonrandomized, open-
label safety and effectiveness study conducted July 2008
through March 2010, patients were enrolled from 264 centers
in 25 countries. Patients were ≥18 years of age, had moderate
to severe active RA for ≥6months, and had inadequate clinical
responses to ≥1 DMARD and/or TNFi therapy. Tocilizumab
8 mg/kg was administered intravenously every 4 weeks. Pa-
tients receiving a TNFi agent before baseline (as monotherapy
or combined with nonbiologic DMARDs) replaced it with
tocilizumab; patients receiving DMARDs alone added toci-
lizumab to their regimens; and patients receiving a TNFi agent
alone discontinued it and initiated tocilizumab monotherapy.
DMARDswere maintained at stable doses (choice and dose at
investigator discretion); if DMARDs were poorly tolerated (as
determined by the investigator), tocilizumab was administered
as monotherapy without a washout period. The DMARD
dosage was modified (reduced) only for safety reasons. Oral
corticosteroids (≤10 mg/day prednisone or equivalent) and
nonsteroidal anti-inflammatory drugs (NSAIDs) had to be
used at stable doses for at least 25 of 28 days before treatment
(day 1). Oral corticosteroids were to be kept constant through-
out the study unless tapering was required for safety reasons.
If MTX-related adverse events (AEs) or laboratory abnormal-
ities developed, dose reduction or change in route was con-
sidered for the patient before study withdrawal. Ethical and
regulatory approval and patients’ written informed consent
were obtained in accordance with the Declaration of Helsinki;
Good Clinical Practice was followed.
Assessments
Safety endpoints included AEs, serious AEs (SAEs), serious
infections, neutrophil counts, and liver transaminase levels.
Effectiveness endpoints included ACR20/50/70/90 responses,
European League Against Rheumatism (EULAR) responses,
DAS28 using erythrocyte sedimentation rate, and simplified
and clinical disease activity index (SDAI and CDAI, respec-
tively). Health Assessment Questionnaire–Disability Index
(HAQ-DI) data were also collected. For individual compo-
nents, missing data were imputed using last-observation-
carried-forward until withdrawal for joint counts only; for
ACR and EULAR responses, missing data were considered
no response. Safety and effectiveness were assessed monthly.
Statistical analyses
In this exploratory analysis, which addresses prespecified
protocol-defined study objectives, patients were grouped ac-
cording to initial treatment: tocilizumab monotherapy (mono-
therapy group) or tocilizumab plus ≥1 DMARD (combination
group). Descriptive statistics were used for incidences of AEs
and SAEs, and two-sided Clopper–Pearson 95 % confidence
intervals were calculated unless specified otherwise. To test the
“tocilizumab monotherapy=combination” hypothesis for effec-
tiveness in this nonrandomized setting, logistic or analysis of
covariance (ANCOVA) models adjusted for previous treatment
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(DMARD-IR/TNFi-IR [TNFi previous use: >2 months before
baseline vs TNFi recent use: ≤2months before baseline], known
to have different efficacy outcomes [10]) were used with base-
line DAS28, CDAI, or SDAI, as applicable, as relevant con-
founders. For two key endpoints, ACR50 response and DAS28
change, supportive post hoc analyses used propensity scores
[11] computed using a logistic regression model (Electronic
supplementary material (ESM) Table S1). Five matched groups
were created based on quintiles of the score. Overall DAS28
difference and Cochran–Mantel–Haenszel statistics for ACR50
response were computed; propensity score was included as a
covariate in multivariate models.
Results
Patients
The safety and intent-to-treat (ITT) populations included 1,681
patients (239 [14 %], monotherapy; 1,442 [86 %], combination
therapy; ESM Fig. S1). Overall, patients had established RA
(mean duration, 9.6 years) with high disease activity (mean
DAS28, 6.0) and were highly treatment experienced (mean
number of previous nonbiologic DMARDs [not including
current treatment], 1.3; 42 % had used TNFi agents [mean,
1.4]; Table 1). Disease duration and many baseline disease
activity measures were higher in the monotherapy group,
consistent with the fact that the majority (72 %) of monother-
apy patients were TNFi-IR. In the combination group, MTX
was the most common DMARD (79 %); 3 % of monotherapy
patients started a DMARD (all MTX) during the study.
Safety
The frequencies of AEs (82.4 vs 76.6 % of patients in the
monotherapy and combination groups) and AEs leading to
withdrawal (5.4 vs 5.1 %) were similar between treatment
groups (Table 2). The incidences of SAEs (19.4 vs 20.2/100
patient-years in monotherapy and combination therapy groups)
and serious infections (4.6 vs 5.2/100 patient-years), which
were the most common SAE, were also similar. Grade 3/4
neutropenia and transaminase elevations occurred less frequent-
ly with monotherapy than with combination therapy (treatment
modifications after laboratory events were made according to
the tocilizumab label). Three of four reported deaths occurred in
the combination therapy group (Table 2 [10]).
Effectiveness
Eighty-seven percent of the ITT population completed the
study (complete data for DAS28 and ACR core set (ESM
Table S2) were available for 87 and 83 % of patients,
respectively). Percentages of patients achieving ACR20/50/
70/90 responses at week 24 were 66.9, 46.6, 26.4, and 8.7 %,
respectively, and were similar between treatment groups
(maximum difference, 3.7 %; p>0.12, all comparisons, in-
cluding an analysis of ACR50 using propensity scores;
Fig. 1a, ESM Table S1). ACR20/50/70 responses occurred
as early as week 4 and improved through week 24 (ESM
Fig. S2).
At week 24, no statistically significant difference was
found between treatment groups in EULAR good/moderate
responses, DAS28<2.6 (remission), or DAS28 low disease
activity (LDA; Fig. 1b). EULAR good/moderate responses
and DAS28<2.6 were achieved as early as week 4, and
percentages of patients achieving EULAR good/moderate
responses were maintained through week 24 (ESM
Figs. S3A, S3B). Percentages with DAS28<2.6 increased
through weeks 20 and 24 in the monotherapy and combination
groups, respectively (ESM Fig. S3B); overall, DAS28<2.6
was achieved in 56.8 % of patients. At week 24, numerically
higher proportions of combination therapy patients than
monotherapy patients achieved CDAI and SDAI LDA; CDAI
and SDAI remission rates were similar (Fig. 1b), as were
proportions of patients achieving ACR/EULAR Boolean re-
mission (11.3 % monotherapy vs 11.9 % combination; p=
0.54). Decreases from baseline in DAS28 (mean±standard
deviation, −3.41±1.49 monotherapy vs −3.43±1.43 combi-
nation), CDAI, and SDAI were also similar between treatment
groups, with nonsignificant differences in univariate
(Wilcoxon rank-sum test; Fig. 1c) or multivariate
(ANCOVA) analyses, including analysis of DAS28 change
using propensity scores (p>0.33 for all analyses; ESM
Table S1). Differences in effectiveness between treatment
groups were small and nonsignificant in the subgroups of
patients with and without previous TNFi therapy (Fig. 1c
and d, ESM Table S3).
Decreases in joint counts from baseline to week 24 were
similar between treatment groups (Fig. 1d). At week 24, de-
creases in HAQ-DI were comparable between groups (differ-
ence, 0.03; p=0.48), but a higher percentage of combination
therapy patients (73.4 %) than monotherapy patients (68.4 %)
achieved clinically meaningful improvement in HAQ-DI (p=
0.030; ESM Fig. S4). Effectiveness outcomes in patients in the
combination therapy group who received methotrexate (ESM
Table S4) and in the monotherapy group were similar.
In a subset of study centers, patients who experienced at least
moderate EULAR response after 24 weeks of treatment were
eligible to enter a long-term extension study. Mean DAS28,
DAS28<2.6 responders, ACR20/50/70/90 responders, and per-
centages of patients who achieved clinically meaningful im-
provement in HAQ-DI were similar between treatment groups
after 6 months of the extension study (ESM Table S5).
No evidence for an interaction between baseline DAS28 and
treatment typewas found usingmodels for DAS28 andACR20,
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ACR50, and EULAR responses at week 24 with additional
adjustment for previous treatment. This indicates that baseline
disease activity is not a valuable response predictor for guiding a
choice between monotherapy and combination therapy.
Discussion
In contrast to most phase 3 studies, ACT-SURE evaluated a
population treated closer to actual clinical practice. Patients
were from tertiary academic centers, nonacademic centers,
and private practices with virtually no restrictions on previous
DMARD and TNFi types, dosages, and combinations. Pa-
tients could be treated with a variety of concomitant medica-
tions including add-on DMARDs, NSAIDs, and corticoste-
roids. Our focus was on the comparison between TCZ used as
monotherapy or in combination with nonbiologic DMARDs.
Relevant limitations of this study were the open-label de-
sign, which potentially introduced bias because clinical as-
sessments were not performed in a blinded manner, the ab-
sence of randomization, the focus on short-term safety and
Table 1 Baseline demographics and characteristics
Tocilizumab monotherapy
n=239
Tocilizumab+DMARD (s)
n=1,442
All patientsN=1,681 pa
Female, % 82 81 81 0.79 (F)
Age, years 55.2 (12.3) 53.2 (12.3) 53.5 (12.3) 0.034 (W)
Duration of RA, years 11.0 (9.7) 9.4 (8.6) 9.6 (8.8) 0.0050 (W)
DAS28 6.2 (1.3) 5.9 (1.2) 6.0 (1.2) 0.0010 (W)
SJC 14.0 (10.7) 12.6 (8.9) 12.8 (9.2) 0.22 (W)
TJC 25.5 (15.9) 22.4 (14.8) 22.8 (15.0) 0.0030 (W)
Patient global VAS 66.6 (20.7) 61.8 (21.2) 62.5 (21.2) 0.0015 (W)
Physician global VAS 62.4 (18.4) 58.2 (17.7) 58.8 (17.9) 0.0008 (W)
Patient pain VAS 61.3 (22.5) 56.9 (22.6) 57.5 (22.6) 0.0047 (W)
CRP, mg/dL 2.5 (2.8) 1.8 (2.8) 1.9 (2.8) <0.0001 (W)
ESR, mm/h 44.6 (28.5) 38.3 (26.5) 39.2 (26.8) 0.0010 (W)
HAQ-DI 1.7 (0.6) 1.5 (0.6) 1.5 (0.6) <0.0001 (W)
CDAI 36.5 (15.0) 34.0 (13.4) 34.3 (13.6) 0.019 (W)
SDAI 38.9 (16.1) 35.8 (14.2) 36.3 (14.5) 0.0047 (W)
DMARD-IR, n (%) 66 (28) 910 (63) 976 (58) <0.0001 (C)
TNFi previous use,b n (%) 62 (26) 236 (16) 298 (18)
TNFi recent use,c n (%) 111 (46) 296 (21) 407 (24)
Baseline DMARD use, %
MTX 0 79 67
Hydroxychloroquine 0 16 14
Sulfasalazine 0 13 11
Leflunomide 0 13 11
Baseline oral corticosteroid use, n (%) 124 (51.9) 733 (50.8) 857 (51.0)
Baseline oral corticosteroid dose, mg/dd 7.8 (3.6) 7.1 (3.5) 7.2 (3.5)
Baseline DMARD dose
MTX, mg/week 0 17.5 (7.3) 17.5 (7.3)
Hydroxychloroquine, mg/day 0 331.8 (151.0) 331.8 (151.0)
Sulfasalazine, g/day 0 1.9 (0.6) 1.9 (0.6)
Leflunomide, mg/day 0 18.4 (4.6) 18.4 (4.6)
Data are presented as mean (SD) unless stated otherwise
VAS Visual Analogue Scale
a Between-group comparisons: F Fisher exact test; W Wilcoxon rank sum test; C chi-square test for no association
b Patients who did not use TNFi for >2 months before baseline
c Patients who used TNFi for ≤2 months before baseline
dDose in prednisone equivalents, considering only patients receiving corticosteroids
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clinical outcomes, and the discontinuation of DMARDs at
study entry if poorly tolerated, at the discretion of the rheu-
matologist. Monotherapy patients had more severe disease at
entry, reflecting the fact that this population consisted primar-
ily of TNFi-IR patients. Reports indicate that approximately
one-third of RA patients using biologics receive them as
monotherapy [2]. This observation is in line with the rate of
tocilizumab monotherapy in TNF-IR patients (25 %); howev-
er, only 7 % of DMARD-IR patients received tocilizumab
monotherapy as their first biologic. Additional factors such as
lack of efficacy and poor adherence may also contribute to
DMARD discontinuation over time during biologic treatment
[12].
Slightly higher incidences of transaminase elevations and
neutropenia with monotherapy were observed but were not
associated with severe clinical consequences. Overall the
safety profiles in patients receiving tocilizumab monotherapy
and combination therapy overlapped, consistent with results
of a recent double-blind study [9]. A larger study would be
needed for an appropriate comparison of rates of uncommon
events such as serious infections.
This exploratory analysis did not indicate a sizable differ-
ence in clinical effectiveness between tocilizumab
monotherapy and combination therapy. To account for poten-
tial confounders, including previous treatments, multivariate
analysis and propensity scores were used. Multivariate analy-
sis confirmed previous reports from ACT-SURE suggesting
that TNFi-IR patients represent a difficult-to-treat population
in whom tocilizumab is slightly less effective than it is in
TNF-naive patients [10]. However, in both TNFi-IR and
DMARD-IR subpopulations, the effectiveness of monothera-
py was comparable to that of combination therapy at week 24.
Retrospectively, this study would have had at least 80 %
power to detect a difference of 0.3 in DAS28 change and a
9.5 % ACR50 response difference. Thus, differences in effec-
tiveness generally considered clinically relevant would likely
have been identified.
These data are consistent with findings in other tocilizumab
monotherapy trials. In MTX-naive or 6-month MTX-free
patients and in MTX-IR patients, tocilizumab monotherapy
resulted in higher ACR responses than MTXmonotherapy [6,
8]. The efficacy of tocilizumab monotherapy was also dem-
onstrated in a double-blind, head-to-head trial against
adalimumab monotherapy in patients for whom MTX was
considered inappropriate (because of lack of efficacy or intol-
erance) [13]. In most clinical trials, efficacy did not differ
Table 2 Safety outcomes
Tocilizumab monotherapy
n=239
Tocilizumab+DMARD (s)
n=1,442
All patients
N=1,681
Exposure, 100 PY 1.08 6.59 7.67
AEs, % (95 % CI)a 82.4 (77.0, 87.0) 76.6 (74.3, 78.7) 77.4 (75.3, 79.4)
SAEs, % (95 % CI)a 7.9 (4.9, 12.1) 7.8 (6.4, 9.3) 7.8 (6.6, 9.2)
SAEs, rate/100 PY (95 % CI)b 19.4 (12.0, 29.7) 20.2 (16.9, 23.9) 20.1 (17.0, 23.5)
AEs leading to withdrawal, % (95 % CI)a 5.4 (2.9, 9.1) 5.1 (4.0, 6.3) 5.1 (4.1, 6.3)
Infections, % (95 % CI)a 38.1 (31.9, 44.6) 34.9 (32.4, 37.4) 35.3 (33.0, 37.7)
Serious infections, % (95 % CI)a 2.1 (0.7, 4.8) 2.1 (1.5, 3.0) 2.1 (1.5, 3.0)
Serious infections, rate/100 PY (95 % CI)b 4.6 (1.5, 10.8) 5.2 (3.6, 7.2) 5.1 (3.6, 6.9)
Deaths, n 1e 3f 4
Grade 3/4 neutropeniac at ≥1 time point, % 1.7 3.3 3.1
ALTshift from normal at baseline to >1.5–3× ULN at any time,d
% (n)
9.2 (22) 12.9 (186) 12.4 (208)
ALT shift from normal at baseline to >3× ULN at any time,d %
(n)
1.7 (4) 2.1 (31) 2.1 (35)
ASTshift from normal at baseline to >1.5–3×ULN at any time,d
% (n)
2.9 (7) 5.2 (75) 4.9 (82)
AST shift from normal at baseline to >3× ULN at any time,d %
(n)
0 (0) 0.7 (10) 0.6 (10)
ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, PY patient-year, ULN upper limit of normal
a Two-sided 95 % Clopper-Pearson CI
b Two-sided 95 % Poisson CI
c Only one case of grade 4 neutropenia was reported in the study (tocilizumab+DMARD[s] group)
d Highest postbaseline value
e Streptococcal sepsis, considered possibly related to study medication
f Aortic dissection, considered unrelated to study medication; cardiac arrest (n=2; 1 considered possibly related to study medication)
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Fig. 1 Effectiveness at week 24. a ACR20/50/70/90 responses. b
DAS28, CDAI, and SDAI responses. c Change from baseline in
DAS28, CDAI, and SDAI. d Change from baseline in swollen joint
count (SJC) and tender joint count (TJC). a p values were calculated by
logistic regression analysis adjusted for previous treatment (DMARD-IR/
TNFi-IR [previous TNFi use/recent TNFi use]) and baseline DAS28.
Nonresponder imputation was performed for patients who withdrew or
for whom responses were missing. b Hatched lines represent moderate
EULAR response or low disease activity. EULAR good response:
DAS28≤3.2 at week 24 and change of >−1.2. EULAR moderate
response: DAS28≤3.2 at week 24 and change of <−0.6 to ≥−1.2 or
<−1.2; DAS28>3.2 to ≤5.1 at week 24 and change of <1.2. DAS28:
low disease activity (LDA), ≥2.6 to 3.2; remission, <2.6. CDAI: LDA,
>2.8 to ≤10; remission, ≤2.8. SDAI: LDA, >3.3 to ≤11; remission, ≤3.3.
p values calculated by logistic regression analysis adjusted for previous
treatment (DMARD-IR/TNFi-IR [previous TNFi use/recent TNFi use])
and baseline DAS28, CDAI, or SDAI, as applicable. c TCZmonotherapy
in DMARD-IR patients, n=66; TCZ monotherapy in TNFi-IR patients,
n=173; TCZ+DMARDs in DMARD-IR patients, n=910; TCZ+
DMARDs in TNFi-IR patients, n=532. p values were calculated by
Wilcoxon rank-sum test and compare TCZ monotherapy and TCZ
combination therapy (disregarding the DMARD-IR-TNFi-IR split). d
TCZ monotherapy in DMARD-IR patients, n=66; TCZ monotherapy
in TNFi-IR patients, n=173; TCZ+DMARDs in DMARD-IR patients,
n=910; TCZ+DMARDs in TNFi-IR patients, n=532; p values were
calculated by Wilcoxon rank-sum test and compare TCZ monotherapy
and TCZ combination therapy (disregarding the DMARD-IR-TNFi-IR
split)
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substantially between tocilizumab monotherapy and combi-
nation therapy at 6 months, whereas long-term comparative
data are lacking. Further studies are needed to confirm the
sustained response to tocilizumab monotherapy in RA pa-
tients who experienced inadequate response to previous treat-
ments. In the 24-week analysis of a randomized study in 556
MTX-IR patients [9], no clinically relevant superiority was
demonstrated with an MTX plus tocilizumab add-on strategy
over switching to tocilizumab monotherapy. Small numerical
differences in the primary and some secondary endpoints
favoring combination therapy were not considered clinically
meaningful. Similarly, in an open-label, randomized study in
DMARD-IR or DMARD-intolerant patients, efficacy was
comparable to that of tocilizumab monotherapy and combi-
nation therapy [14]. In two reports, combination therapy with
MTX appeared more effective than tocilizumab monotherapy.
However, one study [15] was a small dose-finding study in
MTX-IR patients, and the other study [16] was a retrospective
analysis of clinical practice in Japan. In the latter, results may
be explained by differences in baseline characteristics, for
which estimates were not adjusted; in particular, disease ac-
tivity, a clear predictor of lower remission rates, was higher for
monotherapy patients than for combination therapy patients
[16].
Monotherapy with TNFi agents has also been studied.
Results from ReACT, a study of adalimumab with a design
similar to that of ACT-SURE, showed larger differences be-
tween TNFi monotherapy and combination therapy [17]. In
addition, randomized controlled trials indicate that a TNFi
agent plus MTX is more effective than either alone [18–20].
In summary, in this 6-month study, tocilizumab had a
comparable safety profile and was similarly effective when
used as monotherapy or as combination therapy with
DMARDs in a broader population of patients. These data
further support that tocilizumab monotherapy is a feasible
treatment alternative for patients for whom combination ther-
apy with MTX is not an option.
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